DBV Technologies S.A. logo
DBV Technologies S.A. DBVT
$ 21.59 -0.12%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

DBV Technologies S.A. Deferred Revenue 2011-2026 | DBVT

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue DBV Technologies S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - 3.2 M 4.36 M 2.79 M 3.25 M 791 K 1.05 M 794 K 127 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
4.36 M 127 K 2.05 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
86.5 M - 2.43 % $ 254 M germanyGermany
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
55.7 M $ 18.33 -0.92 % $ 2.7 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
2.4 M $ 72.81 5.02 % $ 9.74 B usaUSA
I-Mab I-Mab
IMAB
563 K - - $ 866 M chinaChina
Aytu BioScience Aytu BioScience
AYTU
339 K $ 2.72 4.62 % $ 17.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
15.9 M - - $ 40.3 B usaUSA
Adagene Adagene
ADAG
726 K $ 2.99 8.55 % $ 168 M chinaChina
Biogen Biogen
BIIB
55.7 M $ 177.96 -1.07 % $ 25.9 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
1.3 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.69 M - -1.52 % $ 24.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
33.3 K $ 3.12 -1.74 % $ 7.51 B australiaAustralia
Acorda Therapeutics Acorda Therapeutics
ACOR
227 K - -24.86 % $ 820 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
517 K - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
3.74 M $ 1.4 -0.71 % $ 262 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
363 K $ 223.74 -1.05 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
85.7 K - -11.43 % $ 502 K usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 4.13 2.92 % $ 8.99 B israelIsrael
Aravive Aravive
ARAV
4.41 M - -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
300 M $ 110.82 -2.58 % $ 27.2 B germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
283 K - -10.17 % $ 12.2 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
29 M - -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
1.8 M - -5.38 % $ 6.06 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
9.63 M $ 1.85 0.27 % $ 166 M israelIsrael
AIkido Pharma AIkido Pharma
AIKI
240 K - 1.93 % $ 17.4 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
158 M - - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
2.91 M - 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
1.42 M $ 6.68 1.52 % $ 1.38 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
35.6 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
2.66 M - 4.14 % $ 49.1 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
109 M $ 28.17 1.99 % $ 2.32 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
187 M - 0.49 % $ 251 B cayman-islandsCayman-islands